Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

Expert Rev Clin Pharmacol. 2021 Oct;14(10):1183-1188. doi: 10.1080/17512433.2021.1944102. Epub 2021 Jul 9.

Authors

Tuğrul Elverdi¹, Melis Dila Özer Çerme², Tahacan Aydın², Ahmet Emre Eşkazan¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
² Department of Internal Medicine, Cerrahpaşa Faculty of Medicine,Istanbul University-Cerrahpaşa, Fatih,Istanbul,Turkey.

PMID: 34130583
DOI: 10.1080/17512433.2021.1944102

No abstract available

Keywords: Anticoagulant; antiplatelet; bleeding; caplacizumab; thrombosis; thrombotic thrombocytopenic purpura.

Publication types

Editorial

MeSH terms

Fibrinolytic Agents / administration & dosage*
Humans
Purpura, Thrombotic Thrombocytopenic / drug therapy*
Purpura, Thrombotic Thrombocytopenic / physiopathology
Single-Domain Antibodies / administration & dosage*
Single-Domain Antibodies / adverse effects

Substances

Fibrinolytic Agents
Single-Domain Antibodies
caplacizumab